Join the community

Connect now

MyNovocure®: Your Full-Service Support Partner

Get the most from your Optune Gio® treatment journey with 24/7 support from MyNovocure.

Justin, an Optune Gio patient. 


Maria, a MyNovocure Device Support Specialist (DSS).

MyNovocure gives you the information you need to start your treatment with confidence

24/7 Care Center assistance

Whenever you need technical support, help with supply reorders, or travel advice and resources, our US-based Care Center answers the call.

Device logistics

We help coordinate device delivery and setup.

Reimbursement support

We manage your insurance coverage to help minimize your out-of-pocket costs.

Translation services

Training and Care Center support are available in more than 200 languages, including Spanish.

We're ready to help you any time you need us

Call MyNovocure at 1-855-281-9301 or email at support@mynovocure.com.

MyNovocure cannot provide medical advice. Your medical questions will be referred back to your doctor.

We're committed to being there any time you need us

We offer live, virtual, and on-demand support to help you manage your treatment.

Personalized 1-on-1 training

Your dedicated Device Support Specialist (DSS) will deliver personalized training for your device, live or virtually, in your home or doctor’s office.

 

Ongoing assistance from your DSS

Your dedicated DSS is available throughout your treatment, whenever you need hands-on support or education. 

Maria, a MyNovocure DSS.

Complete support tailored
to your needs

Meet the dedicated MyNovocure team committed to supporting Optune Gio users and care partners throughout treatment—hear how they work to ensure you feel cared for, reassured, and never alone.

Get the MyNovocure App

On-demand help from your full-service support partner—use the app to:

  • Get tips and resources
  • Order supplies
  • Track your usage of Optune Gio
 

You can also contact MyNovocure anytime—call

1‑855‑281‑9301 or email support@mynovocure.com. 

Apple App StoreGoogle Play Store
 

To use the app, please ensure that your email and mobile number are registered with MyNovocure by contacting 1-855-281-9301 by phone. App Store is a service mark of Apple Inc., registered in the US and other countries. Google Play and Google Play logo are trademarks of Google LLC.

Applying the arrays
See how
Learn from others
Start the conversation

Important Safety Information

What is Optune Gio® approved to treat?

Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune Gio is used together with a chemotherapy called temozolomide (TMZ) if:

  • Your cancer is confirmed by your healthcare professional AND
  • You have had surgery to remove as much of the tumor as possible

Recurrent GBM

If your tumor has come back, Optune Gio can be used alone as an alternative to standard medical therapy if:

  • You have tried surgery and radiation and they did not work or are no longer working AND
  • You have tried chemotherapy and your GBM has been confirmed by your healthcare professional

Who should not use Optune Gio?

Optune Gio is not for everyone. Talk to your doctor if you have:

  • An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune Gio has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune Gio has not been tested in people with skull defects or bullet fragments, which may cause Optune Gio not to work properly 
  • A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune Gio comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction

Do not use Optune Gio if you are pregnant or are planning to become pregnant. It is not known if Optune Gio is safe or effective during pregnancy.

What should I know before using Optune Gio?

Optune Gio should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Gio.

  • Do not use any parts that did not come with the Optune Gio Treatment Kit sent to you by Novocure or given to you by your doctor
  • Do not get the device or transducer arrays wet
  • If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune Gio treatment

What are the possible side effects of Optune Gio?

Most common side effects of Optune Gio when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression. The most common side effects when using Optune Gio alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers. Talk to your doctor if you have any of these side effects or questions.

 

Please click here for the Optune Gio Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Novocure Websites

This website is intended for people seeking information on Optune Gio.

On this site, patient and healthcare professional videos as well as all images labeled Optune Gio users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals.

All other depictions of patients and caregivers are actor portrayals. Patient images reflect the health status of the patients at the time each photo was taken.

 

All rights reserved.

MyLink, MyNovocure, Novocure, and Optune Gio are registered trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners.

US-OPG-00063 v11.0 June 2026